DBV TECHNOLOGIE/S (NASDAQ:DBVT) Receives “Hold” Rating from Stifel Nicolaus
Stifel Nicolaus reiterated their hold rating on shares of DBV TECHNOLOGIE/S (NASDAQ:DBVT) in a report published on Friday morning, AnalystRatings.com reports.
A number of other brokerages have also recently weighed in on DBVT. JMP Securities dropped their price objective on shares of DBV TECHNOLOGIE/S from $20.00 to $10.00 in a report on Tuesday, March 17th. Bryan, Garnier & Co cut shares of DBV TECHNOLOGIE/S from a buy rating to a neutral rating in a report on Wednesday, March 18th. ValuEngine upgraded shares of DBV TECHNOLOGIE/S from a hold rating to a buy rating in a report on Wednesday, March 11th. Citigroup dropped their price objective on shares of DBV TECHNOLOGIE/S from $14.00 to $10.00 and set a buy rating for the company in a report on Monday, April 6th. Finally, Morgan Stanley dropped their price objective on shares of DBV TECHNOLOGIE/S from $11.00 to $4.00 and set an equal weight rating for the company in a report on Wednesday, March 18th. Five research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock currently has an average rating of Buy and a consensus target price of $10.21.
DBV TECHNOLOGIE/S stock opened at $4.63 on Friday. The company’s 50 day simple moving average is $5.19 and its 200-day simple moving average is $7.39. The company has a market capitalization of $511.92 million, a price-to-earnings ratio of -1.99 and a beta of 2.60. DBV TECHNOLOGIE/S has a 1 year low of $2.02 and a 1 year high of $13.49. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.75 and a current ratio of 3.79.
About DBV TECHNOLOGIE/S
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.